176 related articles for article (PubMed ID: 35815644)
21. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
Cancer Immunol Res; 2024 Apr; ():OF1-OF12. PubMed ID: 38563577
[TBL] [Abstract][Full Text] [Related]
22. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
23. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
24. Clinical and morphological features of large-cell neuroendocrine carcinomas and small-cell lung carcinomas expressing the DLL3 and ASCL1 oncoproteins.
Prieto TG; Baldavira CM; Machado-Rugolo J; Olivieri EHR; Silva ECAD; Silva VG; Ab'Saber AM; Takagaki TY; Capelozzi VL
Braz J Med Biol Res; 2023; 56():e12921. PubMed ID: 38126617
[TBL] [Abstract][Full Text] [Related]
25. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y; Tacheva-Grigorova SK; Sutton J; Melton Z; Mak YSL; Lay C; Smith BA; Sai T; Van Blarcom T; Sasu BJ; Panowski SH
Clin Cancer Res; 2023 Mar; 29(5):971-985. PubMed ID: 36692420
[TBL] [Abstract][Full Text] [Related]
27. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
[TBL] [Abstract][Full Text] [Related]
28. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin.
Ranallo N; Bocchini M; Menis J; Pilotto S; Severi S; Liverani C; Bongiovanni A
Expert Rev Anticancer Ther; 2022 Jun; 22(6):597-603. PubMed ID: 35477310
[TBL] [Abstract][Full Text] [Related]
29. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
31. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J; Egusa EA; Wang S; Badura ML; Lee F; Bidkar AP; Zhu J; Shenoy T; Trepka K; Robinson TM; Steri V; Huang J; Wang Y; Small EJ; Chan E; Stohr BA; Ashworth A; Delafontaine B; Rottey S; Cooke KS; Hashemi Sadraei N; Yu B; Salvati M; Bailis JM; Feng FY; Flavell RR; Aggarwal R
Cancer Res; 2023 Jan; 83(2):301-315. PubMed ID: 36351060
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
Zhang H; Yang Y; Li X; Yuan X; Chu Q
Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
[TBL] [Abstract][Full Text] [Related]
34. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
35. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
[TBL] [Abstract][Full Text] [Related]
36. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M; Yoshida T; Shiraishi K; Goto N; Yagishita S; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Naoki K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Br J Cancer; 2023 Dec; 129(12):2003-2013. PubMed ID: 37731022
[TBL] [Abstract][Full Text] [Related]
37. Evaluating
Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
[TBL] [Abstract][Full Text] [Related]
39. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract][Full Text] [Related]
40. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
